Clinical Trial Update: Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating clarithromycin-based triple therapy plus bismuth as first-line treatment for Helicobacter pylori infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Bismuth subsalicylate (bismuth subsalicylate)
• clarithromycin (clarithromycin)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Helicobacter Pylori Infection | Phase 4 | Status: COMPLETED